Randox Cerebral Arrays on the Evidence Series Immunoanalysers

Home - Archives for 9th November 2018

Randox Cerebral Arrays on the Evidence Series Immunoanalysers

The Evidence is the world’s first protein Biochip Array Technology Analyser (BAT). The awarding winning Biochip Array Technology is a multi-analyte testing platform allowing the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.

The Evidence is a fully automated immunoanalyser which is renowned for higher standards of quality, efficiency and reliability.  It is tailored and more suitable in a wide range of settings including hospital laboratories, clinical laboratories, private and public research applications, veterinary laboratories, forensic and clinical toxicology and pharmaceutical applications.

There are many key features for The Evidence, including the ability to carry out multiplex testing which will allow multiple tests to be carried out from a single patient sample as a result. It reduces the amount of labour spent on the individual tests and therefore saves money and time. The analyser is more suitable for larger laboratories with a throughput of >1500 tests per hour with a fully automated system maximising the walk away time – allowing staff to devote their time to other important tasks.

The multi-analyte barcoded controls and calibrators ensure security, accuracy and reliable laboratory testing. They also allow for full traceability making the overall experience easier. It offers a wide-ranging and diverse test menu which offer more tests than other sole suppliers and this will benefit many research areas including immunology, metabolic, cardiovascular and oncology.

Neurological conditions can affect young and old people and result from damage to the brain, spine or nerves which is triggered by an illness or an injury1. Up to 1 billion people (one in six of the world’s population suffer from neurological disorders from Alzheimer and Parkinson disease, strokes, multiple sclerosis and epilepsy 2. In England the number of deaths from neurological disorders have rose by 39% over the past 13 years3.

Randox offers two Cerebral Arrays which have been designed for the simultaneous measurement of analytes associated with nervous system dysfunctions such as Alzheimer’s disease and multiple sclerosis. The Arrays can measure up to five biomarkers simultaneously. They are suitable for human serum, plasma and cerebrospinal fluid (CSF) samples. Additionally, it offers excellent sensitivity, precision and recovery as well as analytical performance.

For more information on our Evidence Series or Cerebral range of Assays, contact us at EvidenceSeries@randox.com

  1. http://www.neural.org.uk/living-with-a-neurological-condition/what-is-a-neurological-condition
  2. https://news.un.org/en/story/2007/02/210312-nearly-1-6-worlds-population-suffer-neurological-disorders-un-report
  3. https://www.bmj.com/content/360/bmj.k1278

 

 

 


Ireland-U.S. Council honour Randox founder with Business Relations Award

The Ireland-U.S. Council in America have this week presented the founder of healthcare diagnostics company Randox Laboratories with an award marking significant achievement in building relations between Northern Ireland and the United States of America.

Presented to Dr Peter FitzGerald at the 56th Annual Dinner of the Ireland-U.S. Council yesterday evening, the accolade, named the Cúchulainn award, recognizes the efforts of individuals who go above and beyond to support the objectives of the Ireland-U.S. Council – to improve the business bonds and commercial connections between Ireland, Northern Ireland and the United States.

Joining an exclusive line-up of some of the most prominent business figures in both Ireland and the United States recognized by the Ireland-U.S. Council, including CEO of International Airlines Group William Walsh, Dr FitzGerald was presented with the prestigious award at The Metropolitan Club in New York City.

Dr. Peter FitzGerald, Founder and Managing Director of Randox Laboratories, commented;

“I am most honoured to be here this evening to accept the Cúchulainn award from the Ireland-U.S. Council in recognition of the work undertaken by Randox in the United States since the early 1980s when we began to export our diagnostic healthcare products. The United States remains one of Randox’s most important markets, in which we are growing at pace thanks to the ongoing development of innovative new products in not only the healthcare sector, but also the veterinary, research, toxicology and food safety industries.”

The Ireland-U.S. Council was founded in 1962 by a group of American and Irish business leaders as a measure to build an established structure which would encourage closer economic relations, and was initially created to assist in making preparations for the first-ever State Visit of a sitting U.S. President to Ireland by President John F. Kennedy from June 26 – 29 in 1963.

David O’Sullivan, Executive Director of the Ireland–U.S. Council, added;

“Ever since the State Visit to Ireland by President John F. Kennedy, the Ireland-U.S. Council has been engaged in efforts to achieve our transatlantic mission. Dr FitzGerald of Randox Laboratories truly embodies the essence of this mission by aligning his business in Ireland closely with businesses in the US, to maximise the positive outcomes for both parties. We are delighted to present him this evening with the Cúchulainn award – for the significant contributions he has made to the development of closer economic, business and commercial ties between our two nations.”

For further information please email randoxpr@randox.com